314930.KQ Biodyne Co. Ltd.

Healthcare Oil, Gas & Consumable Fuels KOSDAQ
5,890 KRW
Close of Oct 30, 2026
5,210 16,860
Market cap
KRW 174B
P/E
139.1x
P/B
3.95x
ROE
-0.8%
Dividend yield
-
Fundamental score
1.1/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 314930.KQ undervalued?

Graham number

The Graham number of Biodyne Co. Ltd. cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Biodyne Co. Ltd. fundamental analysis

5 of 21 checks passed

ROE 0/2

Low return on equity (-0.8%), below 10%.

ROA 0/1

Return on assets (-0.8%) is below the industry median (1.4%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 1/1

Last year's EPS growth (7,807.0%) is above the industry median (1.8%).

Revenue Growth 0/2

Revenue shrank 16.8% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 0/2

Debt to equity cannot be calculated: debt is not reported or equity is negative.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Cash Runway 2/2

Cash covers 3.4 years of the current cash burn.

PE vs Market 0/1

PE (139.1x) is above the market median (11.3x).

PE vs Industry 0/1

PE (139.1x) is above the industry median (11.4x).

PBV 0/1

Price to book (3.9x) is above the industry median (0.9x).

Graham Number 0/1

The price is above the Graham number (PE x PB = 548.8, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Biodyne Co. Ltd. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Biodyne Co. Ltd.

Biodyne Co., Ltd. engages in the development, manufacture, and sale of liquid-based cytology (LBC) equipment and reagent kits for cancer diagnosis in South Korea. The company offers PATHPLORER solution, which preserves and fixes the collected cells; PATHPLORER LBC system, an equipment for processing liquid cytology samples for cancer diagnosis. It exports its products to Japan, Russia, Portugal, Thailand, and internationally. The company was founded in 1999 and is headquarte…

Full company profile